Nadofaragene firadenovec by Ferring International Center for Malignant Pleural Mesothelioma: Likelihood of Approval
Nadofaragene firadenovec is under clinical development by Ferring International Center and currently in Phase III for Malignant Pleural Mesothelioma. According to GlobalData, Phase III drugs for Malignant Pleural Mesothelioma have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Nadofaragene firadenovec’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nadofaragene firadenovec overview
Nadofaragene firadenovec (Adstiladrin) is a non-replicating adenoviral vector-based gene therapy. It is formulated as suspension for intravesical instillation. Adstiladrin is indicated for the treatment of adult patients with high-risk Bacillus CalmetteGuérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.
#s3gt_translate_tooltip_mini { display: none !important; }
Ferring International Center overview
Ferring International Center (Ferring), a subsidiary of Ferring Holding SA research, develops and markets pharmaceutical products. The company offers products in the fields of reproductive health, endocrinology, gastroenterology, urology, and orthopedics. Its major products include Rekovelle (follitropin delta), for controlled ovarian stimulation; Menopur (HP-hMG) for female and male infertility; and Firmagon (degarelix) for prostate cancer. Its pipeline products encompass rHCG for Triggering FFM and rFSH for male infertility for infertility; FE 202767 for Lactation; RBX2660 enema for difficile infection among others. The company has 11 R&D centres in China, Brazil, India, Israel, Denmark, Japan, Switzerland, the UK and the US. Ferring is headquartered in Saint-Prex, Switzerland.
For a complete picture of Nadofaragene firadenovec’s drug-specific PTSR and LoA scores, buy the report here.
Source link
#Nadofaragene #firadenovec #Ferring #International #Center #Malignant #Pleural #Mesothelioma #Likelihood #Approval
